Welchol Related Published Studies
Well-designed clinical trials related to Welchol (Colesevelam)
Effect of colesevelam on liver fat quantified by magnetic resonance in
nonalcoholic steatohepatitis: a randomized controlled trial. [2012]
Colesevelam hydrochloride powder for oral suspension versus cholestyramine powder for oral suspension: comparison of acceptability and tolerability. [2011.03]
Effects of colesevelam on LDL-C, A1c and GLP-1 levels in patients with type 1 diabetes: a pilot randomized double-blind trial. [2011.02]
Colesevelam hydrochloride powder for oral suspension versus cholestyramine powder
for oral suspension: comparison of acceptability and tolerability. [2011]
Effects of colesevelam on LDL-C, A1c and GLP-1 levels in patients with type 1
diabetes: a pilot randomized double-blind trial. [2011]
The potent bile acid sequestrant colesevelam is not effective in cholestatic pruritus: results of a double-blind, randomized, placebo-controlled trial. [2010.10]
An economic evaluation of colesevelam when added to metformin-, insulin- or sulfonylurea-based therapies in patients with uncontrolled type 2 diabetes mellitus. [2010.09.01]
Effect of the bile acid sequestrant colesevelam on the pharmacokinetics of pioglitazone, repaglinide, estrogen estradiol, norethindrone, levothyroxine, and glyburide. [2010.05]
Colesevelam: in pediatric patients with heterozygous familial hypercholesterolemia. [2010.04.01]
Colesevelam added to combination therapy with a statin and ezetimibe in patients with familial hypercholesterolemia: a 12-week, multicenter, randomized, double-blind, controlled trial. [2010.04]
The effect of colesevelam hydrochloride on insulin sensitivity and secretion in patients with type 2 diabetes: a pilot study. [2010.04]
Effects of chenodeoxycholate and a bile acid sequestrant, colesevelam, on intestinal transit and bowel function. [2010.02]
Colesevelam hydrochloride: efficacy and safety in pediatric subjects with heterozygous familial hypercholesterolemia. [2010.02]
Long-term Safety and Tolerability of Colesevelam HCl in Subjects with Type 2 Diabetes. [2010.01]
Effects of colesevelam, rosiglitazone, or sitagliptin on glycemic control and lipid profile in patients with type 2 diabetes mellitus inadequately controlled by metformin monotherapy. [2010.01]
An economic evaluation of colesevelam when added to metformin-, insulin- or sulfonylurea-based therapies in patients with uncontrolled type 2 diabetes mellitus. [2010]
Colesevelam added to combination therapy with a statin and ezetimibe in patients
with familial hypercholesterolemia: a 12-week, multicenter, randomized,
double-blind, controlled trial. [2010]
Colesevelam: in pediatric patients with heterozygous familial
hypercholesterolemia. [2010]
The effect of colesevelam hydrochloride on insulin sensitivity and secretion in
patients with type 2 diabetes: a pilot study. [2010]
Effects of chenodeoxycholate and a bile acid sequestrant, colesevelam, on
intestinal transit and bowel function. [2010]
Rationale and design of a clinical trial to evaluate metformin and colesevelam HCl as first-line therapy in type 2 diabetes and colesevelam HCl in prediabetes. [2009.09]
Colesevelam hydrochloride therapy in patients with type 2 diabetes mellitus treated with metformin: glucose and lipid effects. [2008.10.13]
Colesevelam HCl effects on atherogenic lipoprotein subclasses in subjects with type 2 diabetes. [2008.10.05]
Effects of colesevelam hydrochloride (WelChol) on biomarkers of inflammation in patients with mild hypercholesterolemia. [2006.09.01]
Colesevelam HCl reduces LDL particle number and increases LDL size in hypercholesterolemia. [2006.04]
Safety and efficacy of colesevelam hydrochloride in combination with fenofibrate for the treatment of mixed hyperlipidemia. [2005.09]
Effects of colesevelam HC1 on sterol and bile acid excretion in patients with type IIa hypercholesterolemia. [2005.07]
Colesevelam HCl and ezetimibe combination therapy provides effective lipid-lowering in difficult-to-treat patients with hypercholesterolemia. [2005.07]
Effect of colesevelam HCl on single-dose fenofibrate pharmacokinetics. [2004]
Effectiveness of colesevelam hydrochloride in decreasing LDL cholesterol in patients with primary hypercholesterolemia: a 24-week randomized controlled trial. [2001.10]
Coadministration of colesevelam hydrochloride with atorvastatin lowers LDL cholesterol additively. [2001.10]
Low-dose combination therapy with colesevelam hydrochloride and lovastatin effectively decreases low-density lipoprotein cholesterol in patients with primary hypercholesterolemia. [2001.06]
Efficacy and safety of combination simvastatin and colesevelam in patients with primary hypercholesterolemia. [2001.04.01]
Colesevelam hydrochloride (cholestagel): a new, potent bile acid sequestrant associated with a low incidence of gastrointestinal side effects. [1999.09.13]
Well-designed clinical trials possibly related to Welchol (Colesevelam)
Effect of bile acid sequestrants on glucose metabolism, hepatic de novo
lipogenesis, and cholesterol and bile acid kinetics in type 2 diabetes: a
randomised controlled study. [2012]
Effects of soy protein on lipoprotein lipids and fecal bile acid excretion in men and women with moderate hypercholesterolemia. [2010.11]
Other research related to Welchol (Colesevelam)
Evaluation of colesevelam hydrochloride for the treatment of type 2 diabetes. [2012]
Colesevelam HCI Added to Background Metformin Therapy in Patients With Type 2 Diabetes Mellitus: A Pooled Analysis From Three Clinical Studies. [2011.08.19]
Effects of colesevelam on glucose absorption and hepatic/peripheral insulin sensitivity in patients with type 2 diabetes mellitus. [2011.08.10]
Clinical efficacy of colesevelam in type 2 diabetes mellitus. [2011.08]
Safety evaluation of colesevelam therapy to achieve glycemic and lipid goals in type 2 diabetes. [2011.03]
Clinical efficacy of colesevelam in type 2 diabetes mellitus. [2011]
Effect of colesevelam hydrochloride on glycemia and insulin sensitivity in men
with the metabolic syndrome. [2011]
Safety evaluation of colesevelam therapy to achieve glycemic and lipid goals in
type 2 diabetes. [2011]
Improved glycemic control with colesevelam treatment in patients with type 2 diabetes is not directly associated with changes in bile acid metabolism. [2010.10]
Colesevelam hydrochloride to treat hypercholesterolemia and improve glycemia in prediabetes: a randomized, prospective study. [2010.07]
Initial combination therapy with metformin and colesevelam for achievement of glycemic and lipid goals in early type 2 diabetes. [2010.07]
The role of colesevelam hydrochloride in hypercholesterolemia and type 2 diabetes mellitus. [2010.07]
The potential role of colesevelam in the management of prediabetes and type 2 diabetes mellitus. [2010.05]
Colesevelam lowers glucose and lipid levels in type 2 diabetes: the clinical evidence. [2010.05]
Colesevelam improves insulin resistance in a diet-induced obesity (F-DIO) rat model by increasing the release of GLP-1. [2010.03]
A 50-week extension study on the safety and efficacy of colesevelam in adults with primary hypercholesterolemia. [2010]
The potent bile acid sequestrant colesevelam is not effective in cholestatic
pruritus: results of a double-blind, randomized, placebo-controlled trial. [2010]
Colesevelam hydrochloride to treat hypercholesterolemia and improve glycemia in
prediabetes: a randomized, prospective study. [2010]
Initial combination therapy with metformin and colesevelam for achievement of
glycemic and lipid goals in early type 2 diabetes. [2010]
Long-term Safety and Tolerability of Colesevelam HCl in Subjects with Type 2
Diabetes. [2010]
Effects of colesevelam, rosiglitazone, or sitagliptin on glycemic control and
lipid profile in patients with type 2 diabetes mellitus inadequately controlled
by metformin monotherapy. [2010]
Effectiveness and tolerability of colesevelam hydrochloride for bile-acid malabsorption in patients with cancer: a retrospective chart review and patient questionnaire. [2009.11]
Colesevelam HCl improves fasting plasma glucose and lipid levels in patients with prediabetes. [2009.11]
Quantitative structure-property relationships modeling to predict in vitro and in vivo binding of drugs to the bile sequestrant, colesevelam (Welchol). [2009.10]
Effect of the Bile Acid Sequestrant Colesevelam on the Pharmacokinetics of Pioglitazone, Repaglinide, Estrogen Estradiol, Norethindrone, Levothyroxine, and Glyburide. [2009.09.29]
Effects of Colesevelam HCl, Rosiglitazone, or Sitagliptin on Glycemic Control and the Lipid Profile in Subjects With Type 2 Diabetes Inadequately Controlled on Metformin Monotherapy. [2009.09.28]
Concomitant reduction in low-density lipoprotein cholesterol and glycated hemoglobin with colesevelam hydrochloride in patients with type 2 diabetes: a pooled analysis. [2009.06]
The role of colesevelam HCl in type 2 diabetes mellitus therapy. [2009.05]
The use of colesevelam HCl in patients with type 2 diabetes mellitus: combining glucose- and lipid-lowering effects. [2009.05]
Colesevelam hydrochloride for the treatment of type 2 diabetes mellitus. [2009.02]
Colesevelam hydrochloride: usefulness of a specifically engineered bile acid sequestrant for lowering LDL-cholesterol. [2009.02]
Colesevelam for the management of type 2 diabetes. [2009.02]
Colesevelam HCl improves glycemic control and reduces LDL cholesterol in patients with inadequately controlled type 2 diabetes on sulfonylurea-based therapy. [2008.08]
Efficacy and safety of colesevelam in patients with type 2 diabetes mellitus and inadequate glycemic control receiving insulin-based therapy. [2008.07.28]
Colesevelam HCl Improves Glycemic Control and Reduces LDL-Cholesterol in Patients with Type 2 Diabetes Inadequately Controlled on Sulfonylurea-Based Therapy. [2008.05.05]
Colesevelam hydrochloride in clinical practice: a new approach in the treatment of hypercholesterolaemia. [2008.04]
The use of colesevelam hydrochloride in the treatment of dyslipidemia: a review. [2007.10]
Rationale and design of a prospective clinical trial program to evaluate the glucose-lowering effects of colesevelam HCl in patients with type 2 diabetes mellitus. [2007.07]
Results of the glucose-lowering effect of WelChol study (GLOWS): A randomized, double-blind, placebo-controlled pilot study evaluating the effect of colesevelam hydrochloride on glycemic control in subjects with type 2 diabetes. [2007.01]
Colesevelam hydrochloride-ezetimibe combination lipid-lowering therapy in patients with diabetes or metabolic syndrome and a history of statin intolerance. [2007.01]
Colesevelam: a review of its use in hypercholesterolemia. [2007]
Lipoprotein effects of combined ezetimibe and colesevelam hydrochloride versus ezetimibe alone in hypercholesterolemic subjects: a pilot study. [2006.12]
Lipid-lowering effects of colesevelam HCl in combination with ezetimibe. [2006.11]
Colesevelam hydrochloride in the management of dyslipidemia. [2006.05]
Effects of colesevelam hydrochloride on low-density lipoprotein cholesterol and high-sensitivity C-reactive protein when added to statins in patients with hypercholesterolemia. [2006.04.15]
Colesevelam HCl reduces LDL particle number and increases LDL size in hypercholesterolemia. [2005.07.08]
Colesevelam: potential uses for the newest bile resin. [2005.03]
Dietary administration of colesevelam hydrochloride does not affect fertility or reproductive performance in rats. [2004.11]
Colesevelam HCl: a non-systemic lipid-altering drug. [2003.05]
Colesevelam hydrochloride. [2002.05.15]
Absorption of colesevelam hydrochloride in healthy volunteers. [2002.03]
Effect of colesevelam on lovastatin pharmacokinetics. [2002.03]
Colesevelam hydrochloride: a novel bile acid-binding resin. [2001.07]
Colesevelam: a new bile acid sequestrant. [2001.01]
Colesevelam. [2001]
Drug interactions with colesevelam hydrochloride, a novel, potent lipid-lowering agent. [2000.12]
Colesevelam hydrochloride: a non-absorbed, polymeric cholesterol-lowering agent. [2000.11]
Other possibly related research studies
Pharmacologic options for aggressive low-density lipoprotein cholesterol lowering: benefits versus risks. [2005.08.22]
Effectiveness and tolerability of ezetimibe add-on therapy to a bile acid resin-based regimen for hypercholesterolemia. [2004.09.15]
Overview of pharmacologic therapy for the treatment of dyslipidemia. [2003.01]
Identifying effective and/or safe doses by stepwise confidence intervals for ratios. [2003.03.30]
Absorption, distribution and excretion of GT31-104, a novel bile acid sequestrant, in rats and dogs after acute and subchronic administration. [1997.05]
New drugs for the treatment of hypercholesterolaemia. [2003.11]
What's new in lipid management? [2003.09]
[New antilipemics: prospects] [2003.01]
|
